{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:53:27Z","timestamp":1787061207781,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of histological inclusion criteria for clinical trials of at\u2010risk metabolic dysfunction\u2010associated steatohepatitis (MASH) is often associated with high screen failure rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To describe the design of a trial investigating tirzepatide treatment of MASH and to examine the effect of new inclusion criteria incorporating the use of the FibroScan\u2010AST (FAST) score on the proportion of patients meeting histological criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SYNERGY\u2010NASH is a Phase 2b, multicentre, randomised, double\u2010blinded, placebo\u2010controlled trial in patients with biopsy\u2010confirmed MASH, F2\u2013F3 fibrosis and NAFLD Activity Score \u22654. New inclusion criteria (FAST score &gt;0.35 and an increase in AST inclusion criterion from &gt;20 to &gt;23\u2009U\/L) were adopted during the trial, allowing us to examine its impact on the qualification rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1583 participants were screened, 651 participants proceeded to liver biopsy and 190 participants were randomised with an overall screen fail rate of 87%. Following the protocol amendment, the overall qualification rate for per\u2010protocol biopsies was minimally changed from 27.5% to 28.9% with considerable variation among different investigator medical speciality types: endocrinology: from 37.5% to 39.3%; gastroenterology\/hepatology: from 26.0% to 23.3%; other specialities: from 21.3% to 29.7%. At 29 sites that performed per\u2010protocol biopsies before and after the amendment, qualification rates changed as follows: all: 26.1% to 29.1%; endocrinology: from 35.0% to 40.9%; gastroenterology\/hepatology: 25.6% to 20.0%; other specialities: from 16.1% to 27.8%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For at\u2010risk MASH trials based on liver histology, the implementation of inclusion criteria with the proposed FAST score and AST cut\u2010offs in this trial was most effective at non\u2010specialist sites.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.18042","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T14:29:06Z","timestamp":1716215346000},"page":"17-32","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Randomised clinical trial: Design of the SYNERGY\u2010NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction\u2010associated steatohepatitis and modification of screening strategy to reduce screen failures"],"prefix":"10.1111","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-1577","authenticated-orcid":false,"given":"Raj","family":"Vuppalanchi","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine Indiana University School of Medicine  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"MASLD Research Center, Division of Gastroenterology and Hepatology University of California at San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4696-8300","authenticated-orcid":false,"given":"Amir","family":"Nikooie","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Tang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-7319","authenticated-orcid":false,"given":"Deborah A.","family":"Robins","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3676-5051","authenticated-orcid":false,"given":"Bram","family":"Brouwers","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2396-7356","authenticated-orcid":false,"given":"Mark L.","family":"Hartman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17846"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17783"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.05.064"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23276"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00634-7"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1892"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00070-5"},{"key":"e_1_2_14_24_1","unstructured":"[FDA] United States Food and Drug Administration.Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Draft guidance. Available at:https:\/\/www.fda.gov\/media\/119044\/download. Published Dec 2018. Accessed 1 May 2019."},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30383-8"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.020"},{"issue":"1","key":"e_1_2_14_30_1","first-page":"957A","article-title":"Cost analysis of triage algorithms to identify patients with Nash+NAS\u22654+F\u22652","volume":"68","author":"Sasso M","year":"2018","journal-title":"Hepatology"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22742"},{"key":"e_1_2_14_32_1","unstructured":"[EMA] European Medicines Agency.Reflection paper on regulatory requirements for the development of medicinal products for chronic non\u2010infectious liver diseases (PBC PSC NASH). Draft. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/scientificguideline\/reflection\u2010paper\u2010regulatory\u2010requirements\u2010development\u2010medicinal\u2010products\u2010chronicnon\u2010infectious\u2010liver_en.pdf. Published 15 Nov 2018. Accessed 1 May 2019."},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13284"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v102.i05"},{"key":"e_1_2_14_35_1","first-page":"407","article-title":"Sensitivity analysis for nonlinear mathematical models","volume":"1","author":"Sobol IM","year":"1993","journal-title":"Math Model Comput Exp"},{"key":"e_1_2_14_36_1","volume-title":"Global sensitivity analysis: the primer","author":"Saltelli A","year":"2008"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.05.059"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.036"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.18042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T01:52:56Z","timestamp":1718070776000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.18042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/apt.18042"],"URL":"https:\/\/doi.org\/10.1111\/apt.18042","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"2024-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}